Previous studies have shown higher prevalences of bronchial hyperresponsiveness (BHR), respiratory symptoms and atopic sensitization among adults in Western Germany than in Eastern Germany. One of the aims of the joint project INGA (INdoor Factors and Genetics in Asthma) is to assess incidence, prevalence and trends for asthma, BHR and atopic diseases over a time period of 11 years (1990±2001) in the former West (Hamburg) and East Germany (Erfurt), with special reference to indoor exposure.
Introduction
One of the aims of the joint project INGA (INdoor factors and Genetics in Asthma) is to assess incidence, prevalence and trends for asthma, bronchial hyperresponsiveness and atopic diseases over a time period of 11 years (1990±2001) in former West and East Germany, with special respect to indoor exposure. As part of the European Community Respiratory Health Survey (ECRHS), a previous study clearly revealed that prevalences of respiratory symptoms, atopic sensitization and bronchial responsiveness among adults were higher in West Germany than in East Germany (1). Nicolai et al. recently reported similar ®ndings in adults (2) . Furthermore, the prevalence of current asthma and hayfever among 9±11-year-old children was found to be signi®cantly higher in West Germany (3) . The factors which cause these striking dierences remain unclear, even though several explanations have been proposed. Possible factors could be exposure to dierent allergens or dierent environmental factors, including outdoor and indoor pollutants (4, 5) . If these factors really caused higher rates in West Germany one might expect a tendency for increased prevalence rates in the East when the exposure factors in East Germany change towards the conditions met in West Germany. The INGA study is the ®rst study to assess respiratory symptoms, lung function and bronchial responsiveness in relation to indoor allergen exposure in a case-control design among adults in West and East Germany. The aim of this paper is to analyse trends in bronchial hyperresponsiveness, respiratory symptoms and lung function among adults in the two German cities: Erfurt (East Germany) and Hamburg (West Germany) after German re-uni®cation.
Material and methods

STUDY AREA
As part of the European Respiratory Health Survey (ECRHS) the cities of Hamburg and Erfurt participated in this study. The city of Hamburg is mainly a commercial and administrative centre located in the north of former West Germany, about 150 km from the North Sea and 50 km from the Baltic Sea. The population of Hamburg consists of about 1?7 million people. The city of Erfurt is a commercial centre with industrial parts located in a shallow basin in the south-west of the former East Germany, with a total population of about 0?21 million.
STUDY DESIGN
The study was designed as a case-control study following a cross-sectional study performed from 1990 to 1992 within the ECRHS. On the basis of the study results of the ®rst survey in 1990±1992 cases and controls were de®ned and followed for an average period of 48?6 months. Every subject willing to participate again attended the centre for a detailed questionnaire including respiratory symptoms, spirometry, methacholine or bronchodilator inhalation tests, skin-prick testing and determination of total and speci®c immunoglobulin E. The study was performed from July 1995 to August 1996. Identical methodology was followed in the two centres. The study protocol had been approved by the local ethics committees and all subjects gave their informed written consent.
SUBJECTS
The database consisted of 1159 subjects in Hamburg and 731 subjects in Erfurt who had participated within the European Respiratory Health Survey (ECRHS). Cases for the present study were de®ned as subjects ful®lling at least one of the following four conditions according to the results from the ECRHS (1990±1992): (i) asthma diagnosed by a physician according to the long questionnaire of the ECRHS (10), (ii) at least one positive speci®c serum IgE (> 0?35 kU l
71
; CAP system, Pharmacia, Sweden) against grass, birch, cat, Dermatophagoides pteronyssinus or Cladosporium herbarum, (iii) at least one positive skin prick test reaction (mean wheal diameter of at least 3 mm) against the allergens mentioned above, (iv) PD 20 FEV 1 2?0 mg methacholine or positive bronchodilator testing. The subjects of the control group did not show anyone of these conditions at the ®rst survey. Based on these criteria, 107 cases and 106 controls were recruited from a random list of 538 cases and 621 controls in Hamburg. Similarly, in Erfurt 115 cases and 109 controls out of 363 cases and 368 controls participated in the INGA study. Table 1 provides a description of the database and subjects' demography. Subjects of the control group were signi®cantly older in Hamburg as compared to Erfurt. Furthermore, the percentages of non-smokers were lower (P50?05) in Hamburg in both the control and case group, and also the percentage of ex-smokers was higher in Hamburg within the control group (P50?01). (7) .
Any subject with a baseline FEV 1 below 70% of the mean predicted value received 200 mg of salbutamol by a metered dose inhaler. Spirometry was performed 10 min after administration of the bronchodilator. A more than 12% increase in FEV 1 was considered a positive response.
SPIROMETRY
Spirometric measurements were performed using pneumotachograph-based electronic spirometers (Master Lab 4 in the Hamburg Centre, and PSC-PC in the Erfurt Centre, Jaeger Co., WuÈ rzburg, Germany) that met published standards (8) . Spirometry was performed according to the ATS standards (9) . To account for potential dierences between the two devices, additional lung function measurements were performed in a set of 44 volunteers with both devices. We found a statistically signi®cant dierence for values of vital capacity (VC), forced expiratory volume in 1 sec (FEV 1 ) and peak expiratory¯ow (PEF); no signi®cant dierence was found in forced vital capacity (FVC). Subsequently, the Pneumoscope device (PC) was considered as the standard device (independent variable) and the Master Lab 4 device (ML) as a dependent variable. The regression equations (standard errors are given in parenthesis) were:
( All mean values obtained by the Master Lab 4 device were corrected according to these regression equations. This procedure was considered to be statistically allowed as it did refer to similar populations measured under identical conditions.
In smokers, spirometry was performed at least 1 h after the last cigarette had been smoked. Subjects had not had an upper respiratory tract infection within the 3 weeks prior to the visit in the laboratory.
QUESTIONNAIRE
The questionnaire used to assess respiratory symptoms such as wheezing, chest tightness and shortness of breath within the last 12 months, medical history, smoking, occupation and social status had been developed according to the validated long questionnaire with 71 items as used in the ECRHS study (10) . The validated German version of the original ECRHS questionnaire was shortened to 40 items as compared to the original version, without changing the questions in their wording.
STATISTICAL ANALYSIS
Data were analysed using the PC statistical software Statistica (Release 4?1). Multiple logistic regression analysis was employed for the binary response variables BHR, DRS 0?1 or 0?05. The distribution of DRS was skewed with some negative values. Therefore, we used the reciprocal transformation 1/(DRS+0?1) to obtain the transformed dose±response slope (TDRS) (6) . Due to the reciprocal transformation, a lower value of TDRS represented a higher methacholine responsiveness. Using this TDRS analysis of trends for bronchial hyperresponsiveness were performed by one-way within subjects (repeated measures) analysis of covariance (ANCOVA).
Baseline lung function data were analysed using multiple linear regression models to assess potential dierences between Erfurt and Hamburg in control and case groups. In all logistic and linear regression models, the eect of smoking habits and educational level was studied using categorical variables. In each model, gender, when appropriate, and age were carried as independent variables. Lung function parameters were compared using Student's t-test for independent samples. Chi-squared tests were used to compare prevalences between groups.
Results
RESULTS OF QUESTIONNAIRE
Results of the questionnaire are given in Table 2 . In the control group there was no statistically signi®cant dierence between the Erfurt and Hamburg groups regarding respiratory symptoms, including wheezing, shortness of breath and nighttime symptoms during the last 12 months. When the results of the two surveys were compared within the control group prevalences for wheezing and shortness of breath had slightly increased in Erfurt between 1990/92 and 1995/96, but these dierences were not statistically signi®cant. In the case group, at the 1995/96 survey, frequencies of respiratory symptoms were statistically signi®cantly dierent as compared to Erfurt, with higher prevalences in Hamburg for wheezing and night-time symptoms (P50?05). Furthermore, the case group in Hamburg included nearly twice as many subjects who, at the second survey, reported a doctor's diagnosed asthma (P50?05) and about ®ve times more current use of asthma medication as compared to Erfurt (P50?01). The use of asthma medication increased signi®cantly between 1990/92 and 1995/96 in Hamburg (P50?01). All other dierences in prevalences between the two surveys were not statistically signi®cant dierent neither in the control nor in the case groups in Hamburg and Erfurt.
BASELINE LUNG FUNCTION
Lung function parameters are given in Table 3 . Mean absolute values of FEV 1 were signi®cantly dierent between Erfurt and Hamburg for the control groups (P50?01) but not for the case groups. FEV 1 (as % predicted) was higher for the control group in Hamburg as compared to Erfurt (109?1% and 102?0%, P50?01) In the case group there was no signi®cant dierence in FEV 1 (as % predicted) between Erfurt and Hamburg; the mean value of FEV 1 % FVC was lower in Hamburg than in Erfurt (81?7% and 83?9%, P50?05). There were no signi®cant dierences in FEV 1 FEV 1 (% predicted) and FEV 1 % FVC between the control group and the case group in Erfurt. In contrast, in Hamburg the case group had a signi®cantly lower absolute values of FEV 1 and FEV 1 (as % predicted) (P50?05). The mean declines in FEV 1 were signi®cantly lower in Hamburg as compared to Erfurt in the control and the case group. Separate analyses for gender showed that these dierences were only signi®cant for men. Table 4 . Mean values of TDRS (SEM) for both centres and both studies are shown in Fig. 1 for the control group. Mean values of TDRS indicated a signi®cantly higher degree of airway responsiveness for the controls in Erfurt as compared to Hamburg. Compared to the results of the ECRHS, there was a signi®cant decrease in TDRS corresponding to a higher degree of airway hyperresponsiveness in Erfurt for the control group (P=0.007, ANCOVA, adjusted for gender, age, smoking status, educational level), whereas the bronchial responsiveness to methacholine did not change signi®cantly between the two studies for the subjects of the control group in Hamburg. Mean values of TDRS 1995±1996 were not statistically signi®cant dierent between Erfurt and Hamburg for the case groups. However, in Hamburg, the TDRS increased signi®cantly (P=0.009, ANCOVA), corresponding to a lower degree of airway hyperresponsiveness for the subjects of the case group compared to the values obtained during the ECRHS. The DRS for the case group in Hamburg decreased signi®cantly only in subjects with asthma medication (P=0?03), but not in the subjects without asthma medication (P=0?20). For the case group, Table 5 . The percentage of subjects with BHR in the control group was higher in Erfurt (13?3%) compared to Hamburg (6?9%) in 1995±1996. Corresponding values for the case group were 31?5% and 28?2% (NS). Furthermore, overall 8?1% (5?6% in Erfurt and 10?3% in Hamburg) of all subjects who showed bronchial hyperresponsiveness to methacholine within the ECRHS, did not show bronchial hyperreactivity within the INGA study. The percentage of subjects who changed from normal responsiveness to hyperresponsiveness between the two studies was 7?1% (10?0% in Erfurt and 5?9% in Hamburg). For comparison, 10?9% of all subjects (10?6% in Erfurt and 11?3% in Hamburg) showed constant bronchial hyperresponsiveness. Table 6 presents the results for the analysis of the shift of BHR using a multi-variate logistic regression model including dierent factors. Univariate analysis showed that females had a higher risk to show constant BHR as compared to male subjects at both surveys, but when the baseline FEV 1 was taken into account, these dierences were abolished. Subjects of the case group in Hamburg showed a signi®cant higher rate of reversion to normal BHR. There were no other signi®cant dierences between Hamburg and Erfurt with regard to shift in BHR. Higher age and a non-smoking status proved to be factors for a constant negative BHR at both surveys. Reported respiratory symptoms were strongly associated with a constant positive BHR (odds-ratio 3?2, P50?01).
BRONCHIAL RESPONSIVENESS
Due to clinical contraindications and refusals by some subjects, methacholine challenges were performed only in 85% of all subjects in Erfurt and 96% in Hamburg, respectively. There were no signi®cant dierences between Hamburg and Erfurt for the survey performed in 1995±1996 regarding the months of the year when methacholine challenges were performed. Compared to the months of the year of the ®rst survey in 1990±1992 there was also no signi®cant dierence for Hamburg or Erfurt. Results of the methacholine challenges and bronchodilation tests are given in
Discussion
Previous results from our follow-up study performed in 1994±1995, using a self-administered questionnaire which was identical to the screening questionnaire of the ECRHS from 1990±1992, indicated that the prevalence of atopic diseases in East and West Germany might already converge (11) . Prevalence rates of asthma attacks, asthma medication use, allergic rhinits and wheezing remained stable in Hamburg but increased signi®cantly in Erfurt, approaching those of Hamburg. However, due to the fact that the symptoms were self-reported, this converging tendency might have been the result of an enhanced awareness among the public and health care providers in East Germany. Therefore, long-term follow-up measurements of atopy (e.g. skin-prick testing or IgE-levels), lung function and determination of bronchial responsiveness are needed.
Recently published results from von Mutius et al. showed increasing prevalences of hayfever and atopy among children in East Germany (12) . However, in that group of children (age 9±11 years) there was no signi®cant change in the prevalence of asthma, respiratory symptoms or bronchial hyperresponsiveness. Any interpretation of results from the INGA study has to take into account that there have been drastic changes towards Western lifestyle in Erfurt within the 5 years between the ECRHS and INGA studies. It is a common belief that environmental factors that may determine the development of atopic sensitization, respiratory symptoms and bronchial hyperresponsiveness, are important predominantly in early life (13, 14) . From this point of view one might expect that a change in environmental conditions would not drastically in¯uence the prevalence rates for sensitization, symptoms or bronchial responsiveness in adults (age 24±50 years).
There are only few data available about long-term follow-up studies on bronchial hyperresponsiveness. Most of these studies addressed children or adolescents (15, 16) . Panhuysen et al. found that in a 25-year follow-up study in adult patients with diagnosed asthma, about 21% of all subjects did not show bronchial hyperresponsiveness at the second test 25 years later (17) . Our data, obtained over a time period of 5 years, show a remission rate for bronchial hyperresponsiveness of about 8% overall. The remission rate was about twice as high in Hamburg as compared to Erfurt. Conversely, the incidence rate for BHR was about twice as high in Erfurt. These results might indicate a converging tendency between Hamburg and Erfurt in terms of bronchial responsiveness. The bronchial reactivity in terms of TDRS decreased in the case group in Hamburg, i.e. subjects were more likely to change from a positive BHR to a negative BHR. In contrast, the prevalence of doctor's diagnosed asthma as reported in the questionnaire and the use of asthma medication increased within the case group in Hamburg (odds-ratio 2?9). This ®nding and the decrease in bronchial hyperresponsiveness might be the result of an improvement in asthma diagnosis and treatment in West Germany. For comparison, bronchial hyperresponsiveness and mild BHR remained unchanged between the two surveys within the control group in Hamburg. The annual incidence rate of asthma was about 1?2% for the case group in Hamburg as compared to about 0?2% for the case group in Erfurt. Previous studies reported a mean annual cumulative incidence of asthma in adults between 0?2 and 0?5% (18, 19) for a general population sample. A direct comparison of these incidence rates is not possible due to the fact that results from the INGA study are based on case-control cohorts, which are not representative of the population in West and East Germany. Irrespective of the dierences between Erfurt and Hamburg, out data con®rm that a greater airway calibre is associated with less BHR. Previous studies have shown that bronchial hyperresponsiveness occurred more often in females than in males and that these dierences were abolished when the lower baseline FEV 1 values were taken into account (7, 20, 21) . Moreover, our data are in line with previous observations that respiratory symptoms are a major risk factor for BHR (22, 23) .
Regarding the prevalences of respiratory symptoms there were no unique trends in the control or case group from Erfurt and in the control group from Hamburg. A signi®cant increase of respiratory symptoms was only found for the case group in Hamburg. This is in line with the higher prevalence of doctor's diagnosed asthma and of the use of asthma medication. These ®ndings indicate that at least for the case group, adults in West Germany are still at higher risk to develop respiratory symptoms and bronchial asthma. However, the fact that bronchial hyperresponsiveness decreased overall within the case group can only be explained by an eect of asthma medication in the subset of treated subjects in this group.
The higher degree of bronchial responsiveness to methacholine in the 1995±1996 survey as compared to the 1990±1992 survey which we found in the control group in Erfurt, was not accompanied by a signi®cant increase of respiratory symptoms. There was only a weak trend for increased prevalences of wheezing and shortness of breath. However, the absolute number of subjects reporting respiratory symptoms was low in all groups and the power of statistical analyses was therefore limited. It was the additional assessment of indoor exposure within the INGA study (data not shown) which limited the total number of subjects to be studied in Hamburg and Erfurt.
Magnitude of the decline in FEV 1 as found in the case and control groups in Hamburg was compatible with ®ndings of previous studies reporting that the decline of FEV 1 is at an average of 30 ml year 71 (24) in healthy nonsmokers throughout life. The mean rate of decline amongst smokers is approximately twice as high. It is known that 15±20% of smokers demonstrate an increased susceptibility to tobacco smoke with a rate of decline of FEV 1 ; approximately twice the mean of all smokers (70± 120 ml year 71 ) (25). Peat et al. found a decline in FEV 1 of 50 ml year 71 in non-smoking asthmatics as compared to 35 ml year 71 in healthy subjects (26) . Regarding the decline in FEV 1 there were no signi®cant dierences between 
BHR 1990±92/ 1995±96
Hamburg and Erfurt in females. Male subjects however showed a signi®cantly higher rate of decline in FEV 1 in Erfurt. The reasons for these dierences remain unclear. At least in the control group these ®ndings might be partly explained by the smoking status with less current smokers and more ex-smokers in Hamburg, but after adjustment for smoking status dierences were still signi®cant. In the control groups, baseline FEV 1 was not dierent between Erfurt and Hamburg at the ®rst survey in 1990±1992. Because of the strong association between airway calibre and bronchial hyperresponsiveness, the signi®cant decrease in transformed dose response slopes which indicated higher bronchial hyperresponsiveness in the control group in Erfurt, was in line with the signi®cantly lower baseline FEV 1 in Erfurt 1995±1996 as compared to Hamburg.
The decrease of the transformed dose response slope in the control group in Erfurt is not likely to be due to changes in methodology because an identical procedure of methacholine challenge has been used in both studies and there was no signi®cant dierence in the months of the year when the two surveys were performed. Also, dierences in participation rate were small in the control group and therefore are unlikely to have biased the dierences in dose± response-slopes for methacholine. This is supported by the fact that there were also no dierences in age, gender, or baseline lung function between participants and nonparticipants.
In conclusion, our data provide objective evidence for the hypothetical possible converging tendency between East and West Germany in terms of bronchial responsiveness. Nevertheless, the reported trends for bronchial hyperresponsiveness should be con®rmed within the next INGAsurvey which will be performed in the year 2000±2001.
It is policy of the joint project INGA to indicate that further analyses of medical data (e.g. trends for atopy) and the analysis of indoor exposure will be part of separate publications.
